The vaccine candidate complements Sanofi’s position in the respiratory vaccines space where the company is present in flu and RSV prevention. It allows Sanofi to offer increased physician and patient ...

Sanofi acquires Vicebio for $1.15 billion, adding a next-gen RSV-hMPV vaccine and ‘Molecular Clamp' tech to strengthen its respiratory vaccine pipeline.

The French pharma will pay $1.15 billion upfront to buy Vicebio and gain access to non-mRNA vaccine candidates against RSV, ...

PARIS] Sanofi agreed to buy UK biotech Vicebio for as much as US$1.6 billion, gaining experimental vaccines and a technology ...

Lockheed Reports Earnings at a Tough Time. Drones and Defense Budgets Are a Worry. For the quarter, Wall Street is looking for earnings per share of about $6.41 from sales of $18.5 billion, according ...

From daycare outbreaks to the dreaded mouth sores, here's what parents need to know about hand, foot, and mouth disease.

Measles is a disease caused by the virus Morbillivirus hominis. It’s an RNA virus in the family Paramyxoviridae—meaning it’s ...

KeyBanc's John Vinh reiterated his Overweight rating for the stock and reaffirmed his $240 target price. GM Earnings Are Coming. Tariffs, EV Tax Credits-and What It Means for the Stock ...

Hospital readmission risk in pediatric patients was higher in those who were first admitted for RSV than in those who were first admitted for influenza or hMPV.

HIV antivirals may be the key to stopping HTLV-1, a deadly virus with no cure. In a decade-long study, researchers successfully suppressed the virus in mice and discovered a way to kill infected cells ...

Sanofi is buying Vicebio for more than $1 billion, picking up an experimental vaccine targeting RSV and another respiratory ...

Around 10 million people globally live with the life-threatening virus HTLV-1. Yet it remains a poorly understood disease ...